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INTRODUCTION
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INTRODUCTION
Guillain Barre Syndrome (GBS) is an acute, self limited, inflammatory, 
autoimmune disorder of the peripheral nervous system triggered usually by a 
bacterial or viral infection or other antecedent events. It affects 0.9 to 2/100,000 
persons  in  a  year,  with  a  worldwide  distribution  and  a  slight  male 
preponderance. Generally at the end of one year of illness, 5% of the patients 
had expired and 15% might be unable to walk. Hence it causes large loss of 
productivity and burdens the health care due to its prolonged morbidity.  It is a 
heterogeneous disorder in its type, severity, pathogenesis and prognosis.
GBS is characterised by a rapidly Progressive weakness of all 4 limbs 
with or without sensory loss, evolving within 4 weeks, followed later by slow 
clinical and electrophysiological recovery.  The subtypes of GBS are several. 
Among  those  which  produce  weakness,  the  common  one  are  Acute 
Inflammatory Demyelinating polyradiculopathy (AIDP), Acute Motor Sensory 
Axonal Neuropathy (AMSAN) and Acute Motor Axonal Neuropathy (AMAN) 
and the rare one are pharyngo-cervico Brachial variant, Bilateral foot drop, and 
bifacial weakness.  Among those which do not produce weakness the common 
one  is  Miller.  Fischer  syndrome  (MFS)  and the  rare  ones  are  Pure  sensory 
variant, and acral parasthesia with areflxia.
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Neurophysiologic  abnormalities  are  often  very  mild  or  occasionally 
normal  in  the  early  stages  of  GBS and  hence  may  not  correlate  well  with 
clinical disability.  AIDP is characterized classically by conduction block with 
also prolongation of CMAP latency and f-wave latency but a normal amplitude. 
AMAN and AMSAN are characterized by reduction or absence of amplitude of 
CMAP and both CMAP and SNAP respectively.
Experimental  evidence implicates autoantibodies to gangliosides as the 
cause  of  the  axonal  subgroup  of  GBS and  MFS.  These  antibodies  may  be 
generated  by  the  immune  response  to  an  infective  organism  such  as 
Campylobacter  jejuni,  cross-  reacting  with  the  epitopes  on  the  axon.   The 
resemblance  of  AIDP  to  experimental  auto  immune  neuritis  suggests 
pathogenetic  mechanisms  involving  T-cell  induced,  macrophage  associated 
demyelination.  This proposed autoimmune etiology lead to the induction of 
immunotherapy. 
Intravenous  Immunoglobulin  (IvIg)  and plasma exchange (PE) are  the 
standard  treatment  options  available  at  present.   Though  both  have  similar 
outcome measures many centers prefer the former because of the convenience 
and safety. Several studies show no or less improvement with steroids when 
compared to placebo.  But in reality the use of steroids is prevalent especially 
when the definite or standard treatment options are either not affordable or not 
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available, but at the same time the physicians are under pressure to use “some 
specific drugs” having anti inflammatory properties.  In the present study also, 
several patients were treated with injection methyl prednisolone and an attempt 
is made to analyze and compare the outcome measures of the patients treated 
with different modalities.
Most  of  the  previous  studies  had  utilized  the  7  point  (0-6)  Hughe’s 
disability grade scale to evaluate the disability at admission and to assess the 
outcome.  In addition to the above scale, we also utilize the MRC disability 
scale (0-10) for assessment.  Those who attain walking with or without support 
are graded to have good outcome (<3 in GBS (Hughe’s) disability scale and <5 
in MRC disability scale) and the poor outcome are for those who are unable to 
walk, ventilator dependence or who had expired. 
It is also important to know, when to transfer the patient to intensive care 
unit and who may require mechanical ventilation.  In this study we have also 
analyzed  the  association  of  some  of  the  clinical  features  related  to  poor 
outcome, including death, ventilatory support and tracheostomy.  
10
AIM OF STUDY
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AIM OF STUDY
1. To  study  the  demographic  variables,  clinical  features  and 
electrophysiological findings in patients with various subtypes of GBS.
2. To assess the predictors of respiratory failure.
3. To analyze the influence of poor prognostic factors on the outcome of 
GBS.
4. To  compare  the  outcome  measures  of  GBS  after  various  treatment 
modalities.
5. To analyze and quantify the mean improvement in GBS after various 
treatment modalities.
12
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REVIEW OF LITERATURE
The term Guillain Barre syndrome (GBS) defines a recognizable clinical 
entity that is characterised by rapidly evolving symmetrical limb weakness, loss 
of  tendon  reflexes,  absent  or  mild  sensory  signs,  and  variable  autonomic 
dysfunctions. Since the virtual elimination of poliomyelitis, GBS has become 
the leading cause of acute flaccid paralysis in western countries.l  The condition, 
however, occurs worldwide, affecting patients of all ages and both sexes. In the 
majority  of  cases,  the neuropathy is  triggered by a bacterial  or  viral  illness. 
Weakness can develop acutely (within days) or subacutely (up to 4 weeks) and 
reaches  a  plateau,  with  subsequent  spontaneous  resolution  of  paralysis. 
Although  the  pathogenesis  of  GBS  remains  incompletely  defined,  there  is 
increasing support  for  the concept  that  GBS results from an aberrant  organ-
specific immune response.2
The diagnosis of GBS remains descriptive. To facilitate epidemiological 
research  and  outcome  assessments  of  therapeutic  trials,  a  set  of  generally 
accepted clinical, laboratory, and electrodiagnostic criteria has been set forth, 
delineating  the  prevailing  clinical  presentation-  acute  inflammatory 
demyelinating  polyneuropathy  (AIDP;3,4  panel).  It  has  become  apparent, 
however, that the clinical spectrum of GBS comprises a heterogeneous group of 
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pathological entities, each with distinctive clinical features and most probably 
with its own pathogenesis. 
Diagnostic criteria for Guillain Barre Syndrome3
Features required for diagnosis
 Progressive weakness of both the legs and arms
 Areflexia
Clinical features strongly supportive of diagnosis
 Progression of symptoms over days to 4 weeks
 Relative symmetry of signs
 Mild sensory symptoms or signs
 Cranial nerve involvement (bilateral facial palsies)
 Recovery  beginning  2-4  weeks  after  progression 
ceases
 Autonomic dysfunction
 Absence of fever at onset
 Elevated cerebrospinal fluid protein with <10 cells/µl
 Typical electrodiagnostic features
Features excluding the diagnosis
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 Diagnosis  of  botulism,  myasthenia,  poliomyelitis  or 
toxic neuropathy
 Abnormal porphyrin metabolism
 Recent diphtheria
 Purely sensory symptoms without weakness
Epidemiology
GBS has been the subject of 35 population-based surveys from defined 
geographical areas of Europe, Australia, and North and Latin America during 
the past  40 years.  In  the  past  20 years,  accuracy of  case  ascertainment  and 
collection have improved. All epidemiological studies, however, continue to be 
hampered  by  the  absence  of  a  reference  diagnostic  test  that  would  allow a 
positive  confirmation  of  the  diagnosis.  Nevertheless,  most  reports  document 
similar  figures  for  annual  incidence.  Such  observations  indicate  that  GBS 
occurs  evenly  throughout  the  western  hemisphere,  without  geographical 
clustering and with only minor seasonal variations.
GBS is  known to  occur  at  all  ages,  though it  is  rare  in  infancy.  The 
incidence remains almost uniform below the age of 40, ranging from 1-3 to 1-9 
per 100 000 annually. Most surveys show a slight peak in late adolescence and 
young  adulthood,  coinciding  with  an  increased  risk  of  infections  with 
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cytomegalovirus and Campylobacterjejuni, and a second peak in the elderly.8-10 
A hospital record-based study from the USA, published in 1997, measured the 
annual  incidence  as  8-6  per  100  000  in  people  over  the  age  of  70; 
GBSassociated  morbidity  and  mortality  increased  in  parallel.11 These 
observations  require  confirmation  and  remain  unexplained.  A  failing  of 
immune-suppressor  mechanisms  in  elderly  people  has  been postulated as  an 
explanation for increased susceptibility to autoimmune disorders.
Preceding events
Antecedent infections
GBS is the prototype of a postinfectious illness;  two-thirds of patients 
report an antecedent, acute infectious illness, most commonly a respiratory-tract 
infection or gastroenteritis that has resolved by the time neuropathic symptoms 
begin.  The  interval  between  the  prodromal  infection  and  the  onset  of  GBS 
symptoms varies between I week and 3 weeks, occasionally longer; it averaged 
I I days in several large series.12  In many instances, the pathogen that caused 
the  prodromal  illness  remains  unidentified.  Although  various  infections  and 
events such as surgery have been put forward as possible triggers, the link with 
GBS is not firmly established and remains anecdotal.
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C jejuni, a major cause of bacterial gastroenteritis worldwide, has become 
recognised as the most frequent antecedent pathogen for GBS. The association 
has  been  documented  in  many  case  reports  and  in  14  large  series  of  GBS 
patients  that  were  collected  prospectively,  together  with  appropriate  case 
controls. Serological or culture evidence of a recent C  jejuni  infection ranged 
from  26%  to  41%  in  series  of  sporadic  GBS  cases  from  the  UK,  the 
Netherlands, the USA, and Japan.13-16  This gastrointestinal pathogen was also 
strongly  associated  with  an  acute  motor-axonal  neuropathy  variant  of  GBS 
observed in yearly summer epidemics among rural children in northern China.17 
In a 2-year prospective study from Hebei Province, China, serological evidence 
of a recent Cjejuni infection was found in 66% of GBS patients, as opposed to 
only 16% of village controls.17  Moreover, C jejuni infections are also the most 
frequent  trigger  of  the  Miller  Fisher  syndrome,  (MFS),  a  variant  of  GBS 
characterised by ophthalmoplegia, ataxia, and
areflexia.18,19
The organism may be cultured from stool for several weeks after the end 
of the diarrhoeal illness. In Japan, the majority of Cjejuni  isolates from GBS 
patients  were  of  Penner  serotype  19  (HS-19),  whereas  this  serotype  was 
respiratory-tract  infection  or  gastroenteritis  that  has  resolved  by  the  time 
neuropathic symptoms begin. The interval between the prodromal infection and 
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the onset of GBS symptoms varies between I week and 3 weeks, occasionally 
longer; it averaged I I days in several large series.12  In many
instances, the pathogen that caused the prodromal illness remains unidentified. 
Although various infections and events such as surgery have been put forward 
as possible triggers, the link with GBS is not firmly established and remains 
anecdotal. Those pathogens for which there is convincing and statistically valid 
evidence of an association with GBS are
listed in the table.
C jejuni, a major cause of bacterial gastroenteritis worldwide, has become 
recognised as the most frequent antecedent pathogen for GBS. The association 
has  been  documented  in  many  case  reports  and  in  14  large  series  of  GBS 
patients  that  were  collected  prospectively,  together  with  appropriate  case 
controls. Serological or culture evidence of a recent C  jejuni  infection ranged 
from  26%  to  41%  in  series  of  sporadic  GBS  cases  from  the  UK,  the 
Netherlands, the USA, and Japan.13-16  This gastrointestinal pathogen was also 
strongly  associated  with  an  acute  motor-axonal  neuropathy  variant  of  GBS 
observed in yearly summer epidemics among rural children in northern China.17 
In a 2-year prospective study from Hebei Province, China, serological evidence 
of a recent Cjejuni infection was found in 66% of GBS patients, as opposed to 
only 16% of village controls.17  Moreover, C jejuni infections are also the most 
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frequent  trigger  of  the  Miller  Fisher  syndrome,  (MFS),  a  variant  of  GBS 
characterised by ophthalmoplegia, ataxia, and
areflexia.18,19
Cytomegalovirus  infections,  experienced clinically  as  upperrespiratory-
tract infection, pneumonia, or nonspecific flu-like illness, account for the most 
common  viral  triggers  of  GBS,  ranging  from 10% to  22% in  several  large 
series.9.12.27 Cytomegalovirus  is  particularly  common  in  young  female  GBS 
patients,  and the clinical picture is notable for prominent involvement of the 
sensory  and  cranial  nerves.9   Many  such  patients  have  high  serum titres  of 
antibodies reacting with GM2 gangliosides and with sulphated glycolipids.28-30 
The specificity of such antibodies and their significance for the pathogenesis of 
GBS remains unknown. Associations of GBS with Epstein-Barr virus (10%) or 
varicellazoster  virus  are  more  common  than  in  matched  populationsY  The 
association of GBS and HIV-l is well recognized and occurs usually around the 
time of seroconversion.31   Clinical presentation does not differ  from ordinary 
AIDP;  lymphocytic  pleiocytosis  in  the  cerebrospinal  fluid  should  raise 
suspicion of HIV-1 infection, prompting the search for confirmation.
20
GBS and vaccine
Several anecdotal case reports or small case series have linked GBS to 
vaccinations  on  the  grounds  of  a  mere  temporal  association,  but  no  causal 
relation  has  been  established  and  potentially  confounding  coincidental 
infections were not ruled out. There is, however, no doubt that rabies vaccines 
prepared from the infected brain tissues of adult animals carried an increased 
risk  of  inducing  GBS,  probably  because  of  contamination  with  myelin 
antigens.32 Controversy surrounded the alleged association of GBS and receipt 
of swine-flu influenza vaccine, administered to 45 million Americans in 1976 
and 1977. After re-examination of the data, a panel of experts concluded that a 
small  excess  risk  of  developing  GBS  existed  for  up  to  6  weeks  after  the 
immunisation.33   The  cause  was  never  established.  Carefully  conducted 
surveillance studies of subsequent mass influenza-vaccination programmes of 
the US Army found no increased incidence of GBS.34 The possibility that GBS 
might be triggered by live, attenuated, oral poliovirus vaccine was suggested in 
a report from Finland.35  It described an unusually high incidence of GBS within 
weeks  of  a  national  campaign  of  vaccination  with  oral  polio  vaccine.  The 
observation remains unique. Moreover, a careful epidemiological re-evaluation 
identified a coincidental influenza epidemic and widespread persistence of the 
wild-type poliovirus during the relevant period. Both could have contributed as 
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potential triggers to the transient GBS peak occurrence. In addition, the number 
of GBS cases had started to rise before the vaccination campaign.  Thus,  the 
causal  relation  between  GBS  and  administration  of  oral  polio  vaccine  is 
questionable.  In  addition,  a  large  survey  of  GBS  among  children  in  South 
America showed no temporal association or increased incidence of GBS during 
programmes of mass immunisation with oral poliovaccine. Altogether, whether 
oral poliovaccine is associated with increased risk of GBS is still uncertain.36 
Most  other  currently  used  vaccines  do  not  seem to  be  associated  with  any 
increased risk. Surveillance during a mass measles-vaccination programme of 
more than 70 million children in South America  found no increased risk of 
GBS.37   Two case-control  surveys  of  approximately  200  GBS patients  from 
southeast  England,  which  included  individuals  immunised  with  influenza, 
typhoid,  cholera,  and diphtheriatetanus-pertussis  vaccines,  did  not  show any 
significant  association  between  occurrence  of  GBS  and  a  previous 
immunization.38  These  observations  do  not  exclude  an  association,  but  the 
investigators judged that any increase in absolute risk was unlikely to be greater 
than five-fold. Therefore, in any person who has recovered from GBS, the risk 
of any vaccination should be weighed against the risk of exposure.
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Antecedent events for Guillain Barre Syndrome75
Infections
Viral:
EBV
CMV
HIV
Influenza virus
Coxsackie virus
Herpes simplex
Hepatitis A and C viruses
Bacterial:
Campylobacter jejuni
Mycoplasma pneumonia
Escheritia coli
Parasites:
Malaria
Toxoplasmosis
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Systemic illnesses
Hodgkin’s lymphoma
Chronic Lymphocytic Leukemia
Hyperthyroidism
Collagen vascular disorders
Sarcoidosis
Renal disease
Other medical conditions
Pregnancy
Surgical procedures
Bone marrow transplants
Immunizations
Envenomation
24
Clinical spectrum
Acute inflammatory demyelinating polyradiculoneuropathy
Until  very  recently,  the  eponym  Guillain  Barre  syndrome  was  used 
interchangeably with AIDP, which refers to the salient pathological findings: 
the early lymphocytic infiltrates in spinal roots and peripheral nerves, and the 
subsequent  macrophage-mediated  segmental  stripping  of  myelin.  Such 
segmental  loss  of  the  insulating  properties  of  myelin  is  known  to  cause 
profound  defects  in  the  propagation  of  electrical  nerve  impulses,  resulting 
eventually  in  conduction  block  and  in  the  functional  correlate  of  flaccid 
paralysis.39  AIDP  is  the  most  prevalent  form  of  sporadic  GBS  in  western 
countries  and  accounts  for  85-90% of  cases.13  It  is  generally  viewed  as  an 
autoimmune disorder, triggered in most cases by an antecedent bacterial or viral 
infection. The target of the aberrant immune response seems to be within the 
Schwann-cell  surface  membrane  or  the  myelin,  resulting  in  primary 
inflammatory  demyelination  as  the  major  pathological  finding.40,41   Humoral 
immune responses seem to be of particular importance, but there is also clear 
evidence of T-cell activation.
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The precise target epitopes of the immune reaction are not known. Early 
in the course of AIDP there is infiltration of nerves by lymphocytes and, in 
particular, the deposition of activated complement components along the. outer 
Schwann-cell  surface  membrane  of  myelinated  nerve  fibres.   The  myelin 
sheaths of such fibres undergo a process of vesicular disruption, progressing 
from outside inward. These fine structural changes occur before the recruitment 
of macrophages and their invasion of nerve fibres. These findings led to the idea 
that binding of complement-fixing antibodies to epitopes exposed on the outer 
Schwann-cell surface membrane might lead to complement activation, which, in 
turn,  would  initiate  the  disruption  of  compact  myelin;  the  recruitment  of 
macrophages would then complete  the process of segmental  demyelination.42 
These  observations identify  the Schwann cell  or  myelin  as  the target  of  the 
immune reaction, underscoring the importance of circulating antibodies in the 
pathogenesis  of  GBS.  Various  antibodies  to  nerve-cell  components,  notably 
antiglycolipids  such  as  anti-GMI,  have  been  detected  in  serum  from  GBS 
patients,14,17,20,43 but  a  direct  causal  link  to  the  neuropathy  has  not  yet  been 
shown.
AIDP is  viewed  as  a  reactive,  self-limited,  autoimmune  disease.  The 
primary  consequence  of  the  immune  process  is  the  multifocal  disruption  of 
myelin  segments,  which  leads  to  characteristic  electrophysiological  findings: 
slowing  of  nerve-conduction  velocities,  prolongation  of  distal  and  F-wave 
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latencies,  and conduction block.  Once the immune reactions come to a halt, 
repair and remyelination set in promptly, which correlates with a quick and, in 
most  cases,  complete  recovery  from  the  flaccid  paralysis.  In  many  AIDP 
patients,  however,  particularly  those  with  severe  disease,  inflammatory 
demyelination  is  accompanied  by  variable  disruption  and  loss  of  nerve 
axons.44,45   Breakdown  ofaxons  in  this  setting  is  thought  to  be  a  secondary 
"bystander"  event,  caused  possibly  by  intense  inflammation,  oedema,  and 
swelling of nerves.44-47 The degree of complicating axonal loss in AIDP is an 
important  determinant  of  the speed of  recovery,  the lasting deficits,  and the 
ultimate prognosis.48
Acute motor-sensory axonal neuropathy
Over  the  years,  some  case  reports  alluded  to  the  possibility  that  the 
clinical  spectrum  of  GBS  is  more  heterogeneous.  Based  on  clinical, 
electrophysiological,  and pathological observations,  the suggestion was made 
that a similar clinical presentation might result from a primary immune attack 
directed towards nerve axons.49-51  This idea, which became the subject of much 
controversy, is now supported by direct evidence.41,52,53 
Feasby and colleagues49 drew attention to the unusual findings in seven of 
their  GBS patients  who  presented  with  fulminant  onset  of  paralysis  after  a 
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diarrhoeal or flu-like illness. All had severe generalised paralysis and six needed 
assisted ventilation within 2-4 days from onset of neurological symptoms. Serial 
electrophysiological  examinations,  within  2-7  days,  showed very  reduced or 
absent  evoked  responses  on  distal  supramaximal  stimulation  of  motor  and 
sensory nerves, progressing rapidly to total loss of electrical excitability. This 
pattern was most consistent with findings observed in nerve fibres undergoing 
acute axonal degeneration.51  Accordingly, patients showed severe, generalised 
muscle atrophy with delayed and very poor recovery.  Examination of nerve 
tissue  taken  by  biopsy  early  in  the  disease  course  and  in  two  patients  at 
necropsy  after  1  month  and  19 months  from onset  of  the  illness,  disclosed 
severe axonal degeneration of motor and sensory nerve fibres with only scant 
lymphocytes and little demyelination. Changes extended to the most proximal 
portions  of  nerve  roots,  yet  parent  neurons  were  spared  and  retained  the 
capacity for regeneration.46  The pathological findings indicated a severe and 
probably primary insult to motor and sensory nerve axons and led to the concept 
of  an  acute  axonal  form  of  GBS.49   The  observations  were  subsequently 
confirmed  and  extended  by  Griffin  and  colleagues  in  detailed  analysis  and 
morphological study of similar case presentations from northern China.52,53  The 
disorder was notable for the fulminant  onset of severe paralysis and sensory 
deficits. Detailed immunopathology and examination of fine structure in very 
early disease stages provided strong evidence for a primary immune attack on 
nerve  axons.   Griffin  and  colleagues  introduced  the  descriptive  term  now 
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generally used: acute motor-sensory axonal neuropathy (AMSAN).
Acute motor-axonal neuropathy
The concept of axonal variant forms of GBS was further supported by 
case reports of sporadic acute, purely motor-axonal neuropathies, now termed 
AMAN,  which  were  triggered  in  many  cases  by  an  enteric  infection  with 
Cjejuni. Serum samples from such patients contained high titres of antibody to 
gangliosides  (GM},  GDla,  and  GDlb)  and  these  paralleled  the  clinical 
course.50,54,55  Sporadic  AMAN  cases  have  been  observed  worldwide;  they 
represent  10-20% of GBS patients in contemporary prospective series.14 The 
term  AMAN  was  introduced  originally  with  the  case  descriptions  of  acute 
ascending paralysis that had been observed among rural children in northern 
China, occurring annually as a summer epidemic. 76% of Chinese AMAN cases 
were also seropositive for Cjejuni and a substantial number had IgG antibodies 
to  GM1.17   Electro-physiological  examination  and  necropsy  in  some  cases 
confirmed a pure motor and axona neuropathy pattern.41,52,53.
Electrophysiological  studies  showed a  reduction or  absence  of  distally 
evoked compound motor-action potentials--early signs of denervation on needle 
electromyography-but  normal  condttction  velocities  and  normal  action 
potentials in sensory nerves. These observations were also typical for sporadic 
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AMAN  cases.  The  findings  suggest  that  the  axonal  degeneration  primarily 
involves the motor-nerve terminals. These predicted changes were demonstrated 
in muscle and nerve tissue from a sporadic AMAN case. The biopsy samples 
showed severe and selective loss of terminal motor axons, whereas the distal 
sensory fibres were completely intact.56 Yet,  in severe and advanced AMAN 
cases studied by detailed necropsy, the axonal pathology was much more severe 
and widespread. Motor axons were shown to have degenerated along their entire 
length.41   The  earliest  demonstrable  pathological  change  seemed  to  be  the 
binding  of  IgG  and  activated  complement  components  to  the  axolemma  at 
nodes of Ranvier in large motor fibres.52  Macrophages became attracted to such 
nodes  and  tracked  underneath  the  detached  myelin  lamellae  along  the 
periaxonal  space,  dissecting  the  axon  from the  overlying  Schwann  cell  and 
compact  myelin.   Axolemma,  in  contact  with  invading  macrophages,  was 
focally destroyed; axons showed progressive degenerative changes to the point 
of  total  disintegration.53 In  some patients,  however,  who had died early,  the 
morphological changes were very scant despite severe clinical paralysis.
On  the  basis  of  these  observations,  the  sequence  of  events  has  been 
postulated to take place as follows. C jejuni strains associated with the AMAN 
pattern of GBS are known to have in their liposaccharide membrane GM1-like 
epitopes  that  contain  the  Gal((31-3)GaINac  moiety.25 The  host  generates 
antibodies against GM1 or related gangliosides that bear Gal((31-3)GaINac, the 
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terminal disaccharide that is a candidate epitope. Axolemma at nodes of Ranvier 
and at terminal motor axons are enriched with Gal(pa-3)GaINac.57,58  Binding of 
cross-reacting  complement-fixing  antibodies  to  these  epitopes  on  axolemma 
might initially result in potentially reversible physiological failure of conduction 
without morphological change.59,6o Subsequent activation of complement could 
induce  the  observed  early  structural  changes  in  nerve  axons  and  initiate 
recruitment of macrophages, which then cause further axonal damage. Severity 
of axonal destruction might vary, depending on the vigorousness of the immune 
response;  it  could  range  from  limited  degeneration  of  motor  terminals  to 
generalised and more widespread Wallerian-like degeneration of motor fibres.52 
The  time  span of  recovery  would  vary  accordingly.  Regeneration  of  motor-
nerve terminals over the required short distance can happen quickly because the 
potential for nerve regeneration is probably greatest in childhood, which could 
explain the rapid recovery from paralysis in many children with AMAN and 
their overall good prognosis.61
Miller Fisher syndrome
Another  variant  form  of  GBS-the  Miller  Fisher  syndrome  (MFS)-has 
distinct immunological and pathological features. The MFS pattern is triggered 
by certain Cjejuni strains that give rise to a characteristic pattern of antibodies 
to GQ1bganglioside.22,23  IgG antibodies to GQ1bare seen in 96% of MFS cases 
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and  parallel  the  disease  course.  The  antibodies  recognise  epitopes  that  are 
expressed specifically in the nodal regions of oculomotor nerves, but also in 
dorsal-root ganglion cells and cerebellar neurons.26,62  This pattern corresponds 
with the clinical features of ophthalmoplegia, ataxia, and areflexia. Anti-GQlb-
containing  serum  from  MFS  patients  interfered  with  neuromuscular 
transmission  in  a  mouse  phrenicnerve/diaphragm  preparation,  probably  by 
blocking the release of acetylcholine from motor-nerve terminals.63  The effect 
seemed specific, and may offer an explanation for the motor weakness seen in 
patients with MFS.  Antibodies to GQlb cross-reacted with epitopes contained 
in the liposaccharide of MFS-associated C  jejuni  strains, again suggesting the 
possibility of molecular mimicry.19
There are other GBS variants which are relatively rare.76
Pure sensory variant
                         It is charectorised by a rare occurrence of acute sensory 
polyneuropathy  with  elevated  csf  proteins  and  demyelinating  features  on 
electrodiagnostic studies. There is a rapid onset of large fibre sensory loss with 
resultant sensory ataxia, positive Romberg sign, pseudoathetosis, tremor, lesser 
involvement of small fibre sensoryfunction. The important differential diagnosis 
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to  be  considered  are  Sjogren  syndrome  and  paraneoplastic  sensory 
ganglionopathy
Pure Dysautonomia
                        It is a rare variant of GBS, with initial symptoms pertaining to 
gastrointestinal  tract  such  as  abdominal  pain,  vomiting  and  diarrhea  or 
constipation.  There  may  be  possible  history  of  viral  infection.   Orthostatic 
hypotension and syncope may the disabling features.  Although areflexia and 
mild sensory symptoms may be evident, there is no motor weakness.  Routine 
electrodiagnostic studies are normal, hence autonomic testing such as heart rate 
variability, tilt-table testing, sympathetic skin response(SSR), and sweat testing 
(QSART) may be needed. Most people recover slowly after few months.
Pharyngo Cervico Brachial variant
                   It is a rare regional GBS variant, affecting predominantly, cervical, 
brachial or oropharyngeal muscles. Some studies have documented high titres 
of  GT1a  antibodies.  Patients  may  initially  suffer  with  neck  and  pharyngeal 
weakness  which  may  involve  later  the  upper  but  not  the  lower  limbs. 
Electrodiagnostic studies may show demyelinating changes in the upper limbs.
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Other less common  entities are:
1. Paraparetic variant
2. Acral parasthesias with diminished reflexes in either arms or legs.
3. Facial diplegia or abducens  palsies with distal parasthesias
4. Isolated post infectious ophthalmoplegia
5. Bilateral foot drop with upper limb parasthesias.
6. Acute ataxia without ophthalmoplegia.
Laboratory Studies
Cerebrospinal fluid studies
Approximately  90%  of  patients  with  GBS  demonstrate  spinal  fluid 
protein  elevation  without  leucocytosis  at  the  time  of  maximal  weakness. 
Though the range is broad, values greater than 1.0 gm/ dl are rare and suggest 
another diagnosis.  Although there  are usually less than 10 cells / mm3 spinal 
fluid, it is important to remember that a pleocytosis of 10-20cells/mm3 is seen 
in  approximately  5%  of   patients  and  should  not  dissuade  one  from  the 
diagnosis if the clinical and electrophysiological features are otherwise typical77. 
A spinal  fluid cell  count of  more than 50 cells/mm3 suggests  infection with 
human immunodeficiency virus.
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Electro diagnostic studies
AIDP
Several  sets  of  electrodiagnostic  guide  lines  for  the  identification  of 
peripheral nerve demyelination in GBS have been published, and the number of 
patients diagnosed with AIDP can vary greatly depending on which criteria for 
demyelination are applied78-80.  Majority of AIDP patients will fulfill the criteria 
by the end of fourth or fifth week, it is more important to have an appreciation 
for  the  earlier  and  sequential  changes  that  are  likely  to  be  encountered  in 
patients with AIDP.  Conduction block is the hallmark of a demyelinating lesion 
accounting for  the weakness and sensory loss  in AIDP.  Brown and Feasby 
found partial motor conduction block in one or more motor nerves in nearly 
three fourths of AIDP patients within 2 weeks of the onset of paralysis.  To find 
this  high  frequency  of  partial  motor  conduction  block,  however,  needle 
electrode stimulation at proximal sites is required.  About 50% of AIDP patients 
demonstrate prolonged distal motor and F-wave latencies when first studied80. 
Conduction velocities in the demyelinating range occur mostly in third or fourth 
weeks.
Electromyographic findings depend on the extend and severity of axonal 
involvement.  Early in the course, abnormal spontaneous activity is absent and 
motor  unit  potentials  are  normal.   But  volitional  contraction  may  reveal  a 
pattern of fast firing motorunits typical of neurogenic recruitment.  Fibrillations 
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and sharp waves develop after the second week depending on the degree of 
axonal disruption.
AMSAN
 Electrophysiological studies in patients with AMSAN are indicative of 
axonal  loss  at  both  acute  and  chronic  stages.   The  characteristic  feature  is 
marked  reduction  in  the  compound  muscle  action  potential  amplitude  or 
electrical inexitability of motor nerves, which can be found as early as 3-5 days 
of onset46.  Sensory nerve action potential are also lost.  Abundant fibrillation 
potentials and positive sharp waves can appear quite early.
AMAN
In  patients  with  AMAN,  the  main  abnormality  in  motor  conduction 
studies is reduced compound muscle action potential amplitudes and absent F-
wave responses.83,84  Nerve conduction velocity, distal latency and F-minimum 
latency  are  normal.   Partial  motor  conduction  block  or  abnormal  temporal 
dispersion is  absent.   Sensory nerve conduction studies are normal.   Needle 
EMG examination shows fibrillations and positive sharp waves in the affected 
muscles by 2-3 weeks after the onset of weakness.
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Course of illness
Most patients with AIDP become maximally weak within 11-12 days of 
onset and essentially all reach a nadir by 4 weeks.
 Those with AMSAN and AMAN usually reach their nadir within 6 days. 
Occasional  patients  may  have  stepwise  or  stuttering  course.   Despite 
improvement in supportive and immunomodulating therapy, the mortality rate 
remains 3-5% for GBS with predominant weakness.
Prolonged disability occurs in a surprisingly high percentage of cases, 
especially in those with AMSAN.  Many of these patients are still  unable to 
walk, one year after the onset  of their illness.   Permanent  disability,  usually 
affecting the lower limbs and requiring arthrodesis of ankle and foot occur in 
about 10% of patients.   A smaller  percentage of patients  may have residual 
disability, for years with wheelchair dependence and impaired quality of life.85
In a large series involving almost 300 patients, the mean time to onset of 
recovery was 28 days, while the mean time to complete recovery in those with a 
complete response was 200 days.  Rates of clinical recovery at 12 and 24 weeks 
were 70% and 80% respectively.  This indicates that about 20% of patients will 
have a recovery period extending beyond 6 months.  The time and extend of 
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recovery  are  similar  for  both  AMAN  and  AIDP.61  Whereas  patients  with 
AMSAN usually  have more prolonged periods of  recovery and more severe 
neurological residual deficits.
      
Approximately  10%  of  GBS  patients  may  have  a  malignant  course 
characterized  by  prolonged  stays  in  the  intensive  care  units,  ventilatory 
dependence (extending 4-6 months) and longer periods of rehabilitation.  These 
patients usually have AMSAN, with rapid onset of quadriplegia, severe axonal 
changes with reduced motor action potentials.
In general poor prognostic factors identified are75 
1. Older age.
2. Rapid onset prior to presentation.
3. Ventilator dependence.
4. Inexcitable or reduced amplitude motor evoked responses.
5. No treatment.
6. Preceding diarrheal illness
In order to document the stage of illness and to assess a particular effect 
of treatment appropriate scales has to be applied. In GBS studies the 7 point 
Hughes GBS disability  scale  is  the most  popularly  used.  Modified Rankin’s 
38
disability  scale,  MRC  disability  scale  and  functional  evaluation  by  Barthel 
Index are also used for disability assessment.
The following are some of the scales used.
                          
Guillain Barre Syndrome disability Scale86
0 Healthy
1 Minor  symptoms  or  signs  of  neuropathy but  capable  of  manual 
work/capable of running.
2 Able to walk without support of a stick (5m across an open space), 
but incapable of manual work or running.
3 Able to walk with a stick, appliance or support (5m across an open 
space).
4 Confined to bed or chairbound
5 Requiring assisted ventilation (for any part of the day or night)
6 Death
MRC Disability Scale87              
0 Normal
1 No disability, minor sensory signs or areflexia.
2 Mild  disability;  ambulatory  for  200m;  mild  weakness  in  one  or 
more limbs and sensory impairment.
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3 Moderate  disability;  ambulatory  for  50m without  stick;moderate 
weakness MRC grade 4 and sensory impairment.
4 Severe disability; able to walk 10m with support of stick; motor 
weakness MRC grade 4 and sensory impairment.
5 Requires support to walk 5m; marked motor and sensory signs.
6 Cannot walk 5m, able to stand unsupported and able to transfer to 
wheelchair, able to feed independently.
7 Bedridden, severe quadriparesis; maximumstrength MRC grade3.
8 Respirator  and/or  severe  quadriparesis;  maximumstrength  MRC 
grade 2.
9 Respirator and quadriplegia.
10 Death.
Rankin’s disability scale88               
1 No disability
2 Slight disability;unable to carryout some previous activities but 
looksafter own affairs without assistance
3 Moderate  disability;  needs  some  help  but  walks  without 
assisstence.
4 Moderately severe disability; unable to walk and do bodily care 
without help.
5 Severe disability; bedridden, incontinent;  constant nursing care 
needed.
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Treatment
Patients with GBS need to be admitted to hospital for close observation. 
Care for these patients is best provided in tertiary centers, with intensive-care 
facilities and a team of medical professionals who are familiar with the special 
needs of GBS patients. The evolution and severity of the neuropathy is variable; 
it can happen with alarming speed so that intubation and mechanical ventilation 
may be necessary 24-48 h from onset of symptoms. Admission to an intensive-
care unit and ventilatory support is needed in 33% of GBS patients, who will 
often also show haemodynamic instability and autonomic dysfunction. Utmost 
vigilance and anticipation of potential complications are necessary to optimise 
the chances of a favourable outcome. Areas to be aware of include: prevention 
of thromboembolic complications; online cardiac monitoring; serial assessments 
of  the  ventilatory  reserve,  oropharyngeal  weakness,  and  airway  protection; 
appropriate  bowel  care  and  pain  management;  adequate  nutrition,  and 
psychological guidance and support.
Progression of disease varies in duration: about 75% of patients reach 
their nadir within 2 weeks;  92% within 3 weeks and 94% within 4 weeks.64 
After  a  brief  plateau  phase,  improvement  begins  with  gradual  resolution  of 
paralysis  over  weeks  to  months.  Outcome  is  generally  favourable.  An 
epidemiological survey in 1993-94 of 140 GBS patients in southeast England 
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showed that 70% had made a complete recovery 1 year later, 22% were unable 
to run, and 8% were unable to walk unaided. In this series, ten patients (7%) 
died and three patients remained bedridden or ventilator-dependent at 1 year; all 
13  patients  were  over  60  years  old.65Similar  figures  were  reported  in  other 
series.  Several  clinical  factors  have  been  identified  that  assist  in  the  early 
prediction  of  outcome.  The  most  reliable  indicators  for  significant  residual 
disability  at  12  months  from  onset  are:  age  over  60  years,  rapid  disease 
progression to quadriparesis in less than 7 days, need for ventilator support, and 
a mean distal motor amplitude of less than 20% of the lower limit of normal. A 
preceding  diarrhoeal  illness  adds  to  a  poor  prognosis.13  The  mortality  rate 
remains  at  5-8%,  even  with  the  most  modem  intensive-care  medicine.66 
Prognosis is better in children, who need less time on ventilation and show a 
more rapid recovery from paralysis.67
Plasma exchange
Three large, multicentre, controlled trials have demonstrated unequivocal 
benefit  from plasma  exchange  when  it  is  used  within  the  first  2  weeks  of 
disease.  In  the  North  American  trial  of  245  patients  with  severe  GBS,  122 
patients were randomly assigned plasma exchange (five exchanges of 50 mL/kg 
bodyweight each, given over 7-14 days), and 123 were assigned conventional 
treatment.  On average,  patients  treated  by  plasma  exchange  improved  more 
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rapidly, could be weaned from assisted ventilation earlier (24 vs 48 days), and 
reached ambulation 1 month earlier (53 vs 85 days). This meant a considerable 
saving,  because  patients  spent  less  time in  intensive-care  units  and hospital. 
Plasma exchange was ineffective when started later than 2 weeks from onset of 
symptoms.  These  results  were  corroborated  by  two French studies  that  also 
established  that  plasma  exchange  is  beneficial  in  milder  GBS  and  that  it 
improves  long-term outcome.  At  1  year,  71% of  patients  treated  by  plasma 
exchange  recovered  full  motor  strength,  as  opposed  to  52% of  controls.68,69 
Observations were consistent and reproducible, which addresses the criticism 
that has been voiced over the lack of a sham-pheresis control group and thereby 
the lack of allocation concealment.
Within  1-2  weeks  of  initial  improvement  after  plasma  exchange, 
secondary worsening may be seen in about 10% of patients.70   These limited 
relapses  may  be  due  to  persistent  active  disease  or  to  antibody  rebound; 
additional treatments by plasma exchange lead to renewed improvement.71 The 
current recommendations are to use two plasma-exchange treatments for mild 
GBS and four or five for severe GBS, starting as soon as possible on a schedule 
of alternating days. Should the patient show secondary worsening, it is usually 
best  to  resume  additional  plasma-exchange  treatments,  although  intravenous 
infusion with Ig may be used as an alternative. Plasma exchange is reasonably 
safe, but not totally free of risk, particularly in haemodynamically unstable GBS 
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patients.  Such  risks,  the  high  cost,  and  the  limited  availability  of  plasma 
exchange facilities prompted the search for alternative treatments.
High-dose intravenous immunoglobulin
Intravenous  Ig  is  a  promising  therapy  in  various  disorders  with  a 
presumed autoimmune basis,  and has the advantage of low risk and ease of 
application. This therapy was therefore introduced as an alternative to plasma 
exchange.  The  two  treatments  were  compared  for  their  effectiveness  in  a 
multicentre study of 150 GBS patients in the Netherlands.72  Intravenous Ig was 
given at a dose of 0-4 g/kg bodyweight for 5 days consecutively, and plasma-
exchange  treatments  followed  the  conventional  schedule.  At  4  weeks 
significantly  more  patients  showed functional  improvement  with intravenous 
IgG (p=0-024) and the investigators concluded that the two treatments were of 
equal  efficacy.  However,  the two groups were not  equally  matched  and the 
study lacked masking. Therefore, these two treatments were assessed again in a 
large, multicentre, randomised trial coordinated by Hughes.73  Plasma exchange 
was compared with intravenous IgG (Sandoglobulin, 0-4 g/kg bodyweight for 5 
days) and with a combined treatment of plasma exchange (five times over 10-14 
days), followed by intravenous IgG (0-4 g/kg bodyweight for 5 days) in 379 
adult patients with severe GBS. At 4 weeks from randomisation, the functional 
disability-measured  by  a  seven-point  disability  scale--was  assessed  by  an 
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observer unaware of treatment allocation. On analysis, the three groups did not 
differ significantly in this outcome criterion, nor did they differ significantly in 
any of the secondary outcome measures (time to recover unaided walking; time 
to discontinue ventilation; recovery from disability during 48 weeks). The study 
concluded that plasma exchange and intravenous IgG had equivalent efficacy 
and  that  combination  of  the  two  treatments  did  not  confer  a  significant 
advantage.  Because of the ease of application, intravenous IgG is currently the 
preferred treatment of GBS. Limited relapses may also be observed in about 
10% of patients treated with intravenous IgG; most respond equally well to a 
series of repeated infusions.
Corticosteroids
Contrary  to  expectation,  corticosteroids  proved to  be  of  no  benefit  in 
GBS. In a large, double-blind, placebo-controlled, multicentre trial of methyl 
prednisolone (500 mg intravenously for 5 days within 2 weeks of onset) versus 
placebo, the groups did not differ significantly in any of the outcome measures. 
A continuing, multicentre trial in the Netherlands is examining the effects of 
intravenous IgG alone or with high-dose intravenous methyl prednisolone. The 
study  is  based  on  pilot  observations  that  suggested  a  beneficial  interaction 
between intravenous IgG and steroids.74 
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Without doubt, there will be advances in treatment as the pathogenesis of 
GBS is  further  elucidated.  These  advances  should  address  the  needs  of  the 
patients who are left with severe motor sequelae 1 year from onset- about 20% 
of the total. Recovery of these patients depends on axonal regeneration, which 
might  be  promoted  by  administration  of  nerve-growth  factors. 
Immunoregulatory cytokines that are involved in terminating the
disease process are being discovered and may become useful in treatment. More 
importantly, preventive measures that control, or even eliminate certain Cjejuni  
infections will be the best means to lower the incidence of GBS.
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MATERIALS AND METHODS
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MATERIALS AND METHODS
This is a prospective study, conducted during the period of January 2006 
to December 2007.  Those patients who had been admitted with the diagnosis of 
GBS, in the medical,  neuromedical,  emergency medical  or intensive medical 
care unit of Madras Medical College in this period were included in the study. 
The approval  of  the Ethical  committee  of  our institute  was obtained for  the 
conduction of the study.
The inclusion criteria consists of patients who presented with features of 
GBS  based  on  Asbury’s  criteria  which  included  ascending  areflexic 
quadriparesis,  with  or  without  cranial  nerve  dysfunction,  evolving  within  a 
period of four weeks.  We also included patients who presented with features of 
GBS subtypes without prominent weakness.
The exclusion criteria consists of
1. Early and prominent bladder and bowel dysfunction
2. Marked and persistent asymmetry of symptoms and signs
3. Presence of persistent sharp sensory level
4. Features of other diseases like myasthenia gravis, botulism, 
poliomyelitis, porphyria and diphtheria
5. Drug or toxin induced acute neuropathy.
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Data regarding the demographic features like age,  sex distribution and 
month of occurrence, clinical features like antecedent illness,  involvement of 
cranial nerves and autonomic dysfunction were collected.
Electro diagnostic  studies  were  performed on patients  using  the NMS 
machine.  As far as possible bilateral median, ulnar, tibial and peroneal motor 
and F-waves and median, ulnar and sural sensory conduction were done on all 
patients.   The  amplitude  and  latency  of  CMAP (Compound  Muscle  Action 
Potential) and SNAP (), conduction velocity of motor and sensory nerves and 
persistence and minimum latency of F-waves were recorded.  Nerve conduction 
studies helped to confirm and categorize the diagnosis and subtypes of GBS.
The basic biochemical and clinicopathological tests and chest x ray were 
done for all patients.  Cerebrospinal fluid analysis was done whenever possible 
and relevant.  Investigations like liver function tests, thyroid function test, CPK, 
HbsAG, HIV and ABG were done on patients as per the need.
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During admission  patients  were analyzed for  their  disability  using  the 
GBS disability  scale  and MRC disability  scale.   For  patients  with disability 
grade of > 3 in GBS disability scale and for those with progressively increasing 
weakness, the definite treatment options (IvIg or plasma exchange) were started. 
Due  to  non-availability  some  patients  received  only  injection  methyl 
prednisolone.
Patients  were  followed up throughout  their  stay  in  the  hospital. 
Intensive medical care was provided for those patients with advanced stage of 
disease.  Elective intubation was done for those patients who had poor single 
breath count estimation and reduced peak expiratory flow rate and for  those 
with neck muscle weakness and poor cough reflex.  Ventilatory support was 
provided for those in need.  Tracheostomy was performed on those patients who 
tend to require ventilatory support for more than 10 – 14 days.
Complications of prolonged immobility, ventilation, drug side effects and 
catheterization  like  aspiration  and  ventilator  associated  pneumonia,  pressure 
sores, UTI psychosis and DVT were noted and treated accordingly.
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Periodic assessment of their clinical status and disability was done and 
their peak disability was noted.   At the end of 8 weeks duration, reassessment 
was done in their clinical status and prevailing disability score was noted for 
further analysis.
Microsoft excel was used to record the data obtained. The SSEP package 
was  used  for  statistical  analysis.   The  mean  and  standard  deviation  was 
calculated  for  certain  variables,  which  follow  normal  distribution.   The 
association of two categorical variables was evaluated by chi-square tests.  The 
significance of association of certain factors like the treatment adopted and poor 
prognosticators  with  the  outcome  variables  like  death,  ventilator  need, 
tracheostomy and bedridden state was measured by stepwise logistic regression 
analysis.  Statistical significance was considered when the p-value was < 0.05. 
The  mean  improvement  of  disability  score  was  calculated  for  each  of  the 
treatment modality.
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RESULTS
In our study, totally 63 patients were registered from January 2006 to 
December 2007.  These patients included those who were admitted in Medical 
Wards, Emergency Wards, Intensive Medical Care Unit and in the Neurology 
Ward.
Age distribution
Out of the 63 patients, 20 patients were in the age group below 20 years, 
32 patients were in the age group between 20-40 years, 19 patients were in the 
age group between 40-60 years.  Only 2 patients were in the age group above 60 
years.  The distribution is also reflected in the subtypes of GBS.  The following 
table and diagram illustrate the details.
Table-1 Age distribution
Age Group <20 20-40 40-60 >60
Total - 63 10
(15.8%)
32
(50%)
19
(30%)
2
(4%)
AIDP [43] 8 20 13 2
AMSAN [8] 2 3 3 -
AMAN [3] - 2 1 -
MFS [5] - 3 2 -
Pure Sens [1] - 1 - -
Unclassified [3] - 3 - -
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Sex distribution
Regarding the sex distribution there is a slight male preponderance of 35 
males and 28 females among the 63 patients totally registered.  Similar feature 
is noted in the subtypes also.
Table-2 Sex Distribution
Total - 63 Male [35]
(56%)
Female [28]
(44%)
AIDP [43] 23` 20
AMSAN [8] 5 3
AMAN [3] 2 1
MFS [5] 3 2
Pure Sens [1] - 1
Unclassified 2 1
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Antecedent Illness
29 patients in the study had history of antecedent illness preceded by the 
occurrence of GBS.  Upper respiratory infection and diarrhea were noted in 
each of 13 patients.   One patient  had undergone appendicectomy and 1 had 
chicken-pox infection.  One patient was pregnant during the occurrence of the 
illness.  The following table shows the distribution among the subtypes of GBS.
Table-3 Antecedent illness
Total 29/63
(46%)
URI
[13] 
21%
Diarrhea
[13]
21%
Surgery
[1]
Others
[2]
AIDP [21] (48%) 20 8 1
(Appendicectomy)
1-pregnancy
1-chicken 
pox
AMSAN [4] 
(50%)
2 2 - -
AMAN [2] (66%) - 2 - -
MFS [1] (20%) 1 - - -
Unclassfied [1] 
(33%)
- 1 - -
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Cranial Nerve Involvement
Uni or bilateral facial nerve involvement was observed in 22 patients and 
bulbar weakness was observed in 13 patients.  8 patients had both the features. 
Oculomotor weakness was noted in 5 patients who belonged to Miller Fischer 
Syndrome group.  The following table and diagram shows the details.
Table-4 Cranial Nerve Involvement
Total 32
(42.9%)
Facial Only
[14]
Bulbar Only
[5]
Both
(F+B)
[8]
Oculomotor
[5]
AIDP [21] 12 5 4 -
AMSAN [2] 1 - 1 -
AMSAN [1] 1 - - -
MFS [5] - - - 5
Pure Sens [0] - - - -
Unclassified [3] - - 3 -
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Autonomic Dysfunction
Autonomic  disturbances,  which are  generally  considered  bad prognosticators 
were noted in totally 27 patients.  They were tachy or bradycardias, heart blocks 
and postural hypotension.  Table 5 shows the details.
 
Table-5 Autonomic Dysfunction
Total-23 Tachycardia
[17]
Brady 
Cardia
[8]
Postural 
Hypotension
[5]
Heart
Block
[3]
Sudden
Cardiac
Death
[1]
AIDP [18] 13 3 2 1 1
AMSAN [5] 2 3 1 1 -
AMAN [1] - 1 - 1
-
MFS [1] - 1 - -
-
Pure Sens [0] - - - -
-
Unclassified 
[2]
2 - 2 - -
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Clinical features
Among  the  63  patients  totally  registered,  35  had  typical  onset  of 
ascending quadriparesis with areflexia.  4 patients had onset of their symptoms 
in upper limb.  In 18 patients, the onset of weakness was simultaneous in all 4 
limbs and in cranial nerves.  Pain was the predominant presenting feature in 5 
patients though they had weakness and areflexia.  Positive sensory parasthesias 
like pins and needles sensations were noted in 8 patients.  The following table 
gives details about the presenting feature.
Table-6 Mode of Presentation
Typical 
Ascending
Type 
Quadriparesis
Upper 
limb
onset
Simultaneous
Onset In 
Limbs and 
Cr  Nv
Pain as 
predominant
feature
presence 
of  sensory
parasthesia
AIDP 23 3 6 5 8
AMSAN 4 1 3 - -
AMAN - - 3 - -
MFS 3 - 2 - -
Pure Sens - - 1 - -
Unclassifie
d
- - 3 - -
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Mode of Presentation
30
4
18
5
Typical Ascending Type Quadriparesis
Upper limb onset
Simultaneous Onset In Limbs and Cr  Nv
Pain as predominant feature
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Month wise distribution
Table  7 details  the occurrence of  GBS in various months  which shows that 
maximum cases are noted in June to October months.
Table-7 Distribution in months
J F M A M Jn Jly A S O N D
Total 4 5 4 4 4 6 6 8 8 8 3 3
AIDP 3 2 1 3 4 6 6 3 5 6 2 2
AMSAN - 2 1 - - - - 2 - 2 1 -
AMAN - - - - - - - 1 1 - - 1
MFS 1 - 1 1 - - - 1 1 - - -
Pure Sens - 1 - - - - - - - - - -
Unclassified - - 1 - - - - 1 1 - - -
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CSF Analysis
CSF analysis was done in 11 patients in the first week and in 24 patients 
in the second week.  CSF analysis was normal in 10 patients during 1st week and 
in 24 patients during the 2nd week period.
Table-8 CSF results
Total – 
35/63    
Done in I Week [11] Done in II 
week [24]
Normal Abnormal Normal Abnormal
AIDP 8 1 8 7
AMSAN - - 3 1
AMAN - - 1 1
MFS 2 - 2 1
Pure Sens - - - -
Unclassified - - - -
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Peak disability after onset of symptoms (in days)
The timing of occurrence of peak disability from the onset of symptoms 
was noted in all patients.  Generally the rapidity of attaining peak disability is a 
poor prognostic sign.  It was grouped in 4 categories i.e. <2, 3-8, 9-14 and 15-28 
days.
Table-9 Peak disability after onset of Symptoms 
(in days) 
<2
[7] (11%)
3-8
[29] (46%)
9-14
[20] (32%)
15-28
[7] (11%)
AIDP 3 19 14 7
AMSAN 1 5 2 -
AMAN - 3 - -
MFS - 1 4 -
Pure Sens - 1 - -
Unclassified 3 - - -
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Nerve conduction study parameters
The  following  table  details  the  various  nerve  conduction  study 
abnormalities noted in different types of GBS.  Only in 55 out of 63 patients 
Nerve conduction study was possible and in the rest of the patients, the study 
was deferred either due to early death or difficulty to mobilize.  Conduction 
block was  noted  in  19  cases  and F-wave abnormality  in  the  form of  either 
impersistance  or  prolongation  of  minimal  latency  was  noted  in  48  patients. 
Distal latency prolongation was noted in 39 patients.
Table-10 Nerve Conduction Study Parameters
Conduction
Block
(>2.Nerves)
[19]
(34.5%)
F-Wave
Abnormalit
y
[48]
(87.2%)
Distal 
latency
Prolongation
[39]
(70%)
CMAP
[30]
(54.5%)
SNAP
[11]
(20%)
AIDP [40] 19
(47.5%)
37
(92.7%)
39
(97%)
21
(52.5%)
-
AMSAN [6] - 6
(100%)
- 6/6 6/6
AMAN [3] 3 - 3 -
MFS [5] - 2 - - 4
Pure Sens 
[1]
- - - - 1
Unclassfied 
[0]
- - - - -
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Severity of disability with which patient admitted
In the present study, 25 patients were admitted with disability grade of >3 
in  GBS disability  scale  (>5 in  MRC disability  scale)  and 18 were admitted 
below the score.  The score is applicable for the GBS subtypes which cause 
weakness.  The following table and figure shows the details.
Table-11 Severity of disability with which patient presented
<3 -GBS Score
<5-MRC disability
scale
[19]
(30.2%)
>3-GBS Score
>5-MRC 
disability scale
[38]
(60.3%)
AIDP 43 18 25
AMSAN 8 - 8
AMAN 3 1 2
Unclassified 3 - 3
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Admission Disability
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Treatments given for subtypes
In our study IvIg  was given to 18 patients, plasma exchange was given 
for 9 patients and injection methyl prednisolone was given for 25 patients.  No 
specific treatment was provided for 4 patients who presented with very minimal 
disability  and  they  improved  spontaneously.   Three  patients  in  the  study 
presented in a very acute form, with severe disability scores and died before any 
specific form of treatment was initiated.
Table-12 Treatments given for various subtypes of GBS
IvIg
[22]
(34.9 %)
Methyl 
Prednisolone 
[25]
(39.7 %)
Plasma 
Exchange 
[9]
(14.3 %)
No 
Treatment 
[4]
(6.3 %)
Not 
Applicable 
[3]
(4.8 %)
AIDP [43] 18 15 6 4 -
AMSAN [8] 3 3 2 - -
AMAN [3] 1 1 1 - -
MFS [5] - 5 - - -
Pure Sens [1] - 1 - - -
Unclassified 
[3]
- - - - 3
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Subtypes of GBS patients who needed ventilator or ended up in 
death
In the present study, 16 patients needed ventilator support and 10 patients 
expired.  Both the need for ventilator support and occurrence of death, are noted 
in AIDP and AMSAN group and in those patients who presented with very 
severe form of illness (fulminant form of illness).
Table-13 Subtypes of GBS patients who needed 
ventilator or ended up in death
Ventilator 
[20]
(31.7 %)
Death 
[10]
(15.9 %)
AIDP 13 5
AMSAN 4 2
AMAN - -
MFS - -
Pure Sens - -
Unclassified 3 3
70
Among the 63 patients, death was the outcome for 10 patients.  The following table shows the incidence of poor prognostic 
factors among the 10 patients who had expired.
Table-14 The poor prognosticators associated with the patients who had expired
Total -10 % Ventilator
[10]
Autonomic 
disturbance
[9]
Peak of 
weakness 
≤ 8 days
[10]
Bulbar 
dysfunction
[9]
Elderly 
Population
[2]
High grade 
disability* at 
presentation
[9]
Diarrhea
[4]
AIDP [5] 11.6 5 4 5 3 2 4 2
AMSAN [2] 25 2 2 2 1 - 2 1
AMAN [0] - - - - - - - -
MFS [0] - - - - - - - -
Pure Sens [0] - - - - - - - -
Unclassified [3] 100 3 3 3 3 - 1 1
* > 3 score in GBS disability grading 
   > 5 score in MRC disability grading
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Twenty patients in our study needed ventilator support at sometime during the course of hospital stay. Traditionally 
considered poor prognostic factors not only influence death, but also leads to poor respiratory function requiring ventilatory 
support.  The following table shows the incidence of such factors among the ventilated patients.  
Table-15 The poor prognosticators associated with the patients who required ventilatory support
Total %
Death 
[10]
Autonomic 
disturbance 
[13]
Bulbar 
Dysfunction
[9]
Peak 
disability 
reached 
<8 days
[16]
Elderly 
[2]
High grade 
disability at 
presentation*
[19]
Diarrhea 
[7]
Tracheostomy
[5]
AIDP [13] 30 4 8 5 10 2 12 4 5
AMSAN [4] 50 2 3 1 3 - 4 2 0
AMAN - - - - - - - - -
MFS - - - - - - - - -
Pure Sens - - - - - - - - -
Unclassfied [3] 10 3 2 3 3 - 1 1 0
* > 3 score in GBS disability grading 
   > 5 score in MRC disability grading 
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In the study, the outcome assessment is based on whether the patients 
attained  independent  walking  which  is  a  good  outcome  (≤  3  in  GBS 
disability  score  and  ≤  5  in  MRC  disability  scale)  or  did  not  attain 
independent walking which is a poor outcome, at the end of 8 weeks.  Those 
who expired were also included in the poor outcome group.  Apart from 
outcome assessment, ventilator dependence is also a complication related to 
the  severity  of  illness.   Tracheostomy  denotes  that  the  patient  required 
prolonged ventilation again adding to the mortality and morbidity.  These 
outcome related events are analyzed on the back ground of poor prognostic 
factors, which is shown in the Table 16.
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Table-16 Outcome related events for patients with poor prognostic factors
Death Ventilator 
dependenc
e
Tracheos
tomy
Poor 
Outcome*
Good 
Outcome**
Bulbar ± 
Facial 
Weakness
p = 0.002#
AIDP [21] 4 10 4 11 10
AMSAN [2] 1 1 - 2 -
AMAN [1] 1 - - 1 -
Unclassified [3] 3 3 - 3 -
Autonomic 
dysfunction
p = 0.029#
AIDP [17] 4 6 2 8 9
AMSAN [5] 2 2 - 3 2
AMAN [1] - - - 1 0
Unclassified [2] 2 2 - 2 0
Diarrhea
p = 0.165#
AIDP [8] 2 4 3 6 2
AMSAN [2] 1 2 - 2 -
AMAN [2] - - - - 2
Unclassified [1] 1 1 - 1 -
Peak 
disability 
reached 
within 8 
days
p = 0.044#
AIDP [22] 5 8 2 11 11
AMSAN [6] 2 4 - 3 3
AMAN [3] - - - 2 1
Unclassified [3] 3 3 - 3 -
Presented 
with severe 
form of 
disability 
p = 0.001#
AIDP [24] 4 12 5 12 12
AMSAN [8] 2 4 - 4 4
AMAN [2] - - - 1 1
Unclassified [3] 3 3 - 3 -
* > 3 score in GBS disability grading ** ≤ 3 score in GBS disability grading 
   > 5 score in MRC disability grading      ≤ 5 score in MRC disability grading 
# Significance of influence of prognostic factors for poor outcome
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 Among the 18 AIDP patients who were treated,  6 were from mild 
disability group and 12 were from severe disability group.  Among the 15 
AIDP patients who were treated with injection methyl prednisolone 9 were 
from  severe  disability  and  6  were  from  mild  disability  group.   Also  4 
patients with severe disability group were treated with plasma exchange and 
2  from mild  disability  group.   Four  patients  with  AIDP,  who  had  mild 
disability were not treated with any specific form of treatment.
Three AMSAN patients of severe disability were treated with IvIg and 
methyl  prednisolone  and  two  by  plasma  exchange.   All  patients  in  the 
AMSAN group had presented with severe disability. 
One AMAN patient of severe disability group was treated each with 
IvIg and plasma exchange and one with mild disability  was treated with 
methyl prednisolone.  
In the group of 3 patients who presented with very acute and severe 
form of illness, no effective treatment was started before they expired.  The 
following table 17 illustrates the features. 
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Table-17 Treatment adopted in GBS subtypes
IvI
g
Methyl 
Prednisolone
 
Plasma 
Exchange 
Not 
applicable*
No 
Treatment
AIDP
Mild disability 
presentation 
[18]
6 6 2 - 4
Severe 
disability 
presentation 
[25]
12 9 4 - -
AMSAN
Mild disability 
[0] - - - - -
Severe disable 
[8] 3 3 2 - -
AMAN
Mild disability 
[1] - 1 - - -
Sever 
disability [2] 1 - 1 - -
Unclassifie
d
Mild disability 
[0] - - - - -
Severe 
disability [3] - - - 3 -
* Not applicable - Patients died on day 1 or 2 before any form of treatments are effective 
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In the IvIg treated AIDP group of 18 patients, 12 patients had good 
outcome and 6 had poor outcome.  Also in this group one patient expired, 5 
needed ventilatory support and one patient required prolonged ventilatory 
support  as  evidenced  by the  need  for  tracheostomy.   In  the  IvIg  treated 
AMSAN  group  of  3  patients  one  had  poor  outcome  and  2  had  good 
outcome.  In the IvIg treated single AMAN patient the outcome was poor. 
In the plasma exchange treated AIDP group of 7 patients 2 had poor and 5 
had good outcome.
In the plasma exchange treated AMSAN group of 2 patients 1 each 
had  good and  poor  outcome.   In  the  single  AMAN patient  treated  with 
plasma exchange the outcome was good.    
In the methyl prednisolone treated AIDP group of 15 patients, 7 had 
poor  and  8  had  good  outcome,  whereas  3  patients  expired  and  7  had 
ventilator  support.   The  need  for  ventilator  support  was  prolonged  in  4 
patients  who had tracheostomy  also.   In  the  methyl  prednisolone  treated 
AMSAN  group  of  3  patients  all  had  poor  outcome  and  one  required 
ventilator  support,  and  death  occurred  in  one  patient.   In  the  methyl 
prednisolone treated single AMAN patient the outcome was good.
The following table 18 shows the details. 
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Table-18 Comparison of treatment adopted with clinical outcome at 8 weeks 
among GBS subtypes
Death 
[7]
Ventilator 
Support 
[16]
Tracheo
stomy
[5]
Poor 
outcome 
[21]
Good 
outcome 
[30]
Iv Ig [22]
p = 0.410#
AIDP [18] 1 5 1 6 12
AMSAN [3] - - - 1 2
AMAN [1] - - - 1 -
Plasma 
Exchange 
[9]
p = 0.687#
AIDP [6] 1 1 - 2 5
AMSAN [2] 1 2 - 1 1
AMAN [1] - - - - 1
Methyl 
Prednisolone 
[18]
p = 0.134#
AIDP [15] 3 7 4 7 8
AMSAN [3] 1 1 - 3 -
AMAN (1) - - - - 1
# Significance of influence of treatment options for outcome
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In  the  IvIg  treated  AIDP patients  (12)  who  presented  with  severe 
disability  the  outcome  was  poor  in  5  patients  and  good  in  7  patients. 
Ventilator  was  needed  in  4  patients  and  one  had  prolonged  ventilatory 
support.  In the IvIg treated AMSAN patients who presented with severe 
disability  the outcome was poor  for  one  and good for  two.   In  the IvIg 
treated  single  AMAN  patient  who  presented  with  severe  disability  the 
outcome was poor.
In the plasma exchange treated 4 AIDP patients who presented with 
severe  disability  2  had poor  and 2 had good outcome.   One patient  had 
expired in this group after  a ventilator  support.   In the plasma exchange 
treated 2 AMSAN patients who presented with severe disability one each 
had poor and good out come.  In the plasma exchange treated single AMAN 
patient with severe disability the outcome was good.
In the methyl  prednisolone treated 9 AIDP patients  who presented 
with severe disability the outcome was good for 3 and poor for 6 patients.  In 
the  methyl  prednisolone  treated  3  AMSAN patients  who  presented  with 
severe disability the outcome was poor for all 3 patients.
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Table-19 Comparison of treatment options with clinical outcome at 8 weeks 
among GBS subtypes who presented with severe disability
Death Ventilator
Tracheo
stomy
Poor 
outcome
Good 
outcome
Iv Ig
AIDP [12] - 4 1 5 7
AMSAN - 1 - 1 2
AMAN - - - 1 -
Plasma 
Exchange
AIDP [4] 1 1 - 2 2
AMSAN [2] 1 1 - 1 1
AMAN [1] - - - - 1
Methyl 
Prednisolone
AIDP [9] 3 6 3 6 3
AMSAN [3] 1 1 - 3 -
AMAN [0] - - - - -
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The mean improvement in GBS disability scores from admission to 
the end of 8 weeks was calculated for all GBS patients which is shown in the 
table 20 below.
Table-20 Mean improvement in disability scores for 
various treatment options
Disability Scale Treatment Option
Total 
Numbers
Mean 
Improvement
GBS disability 
scale
p = 0.002#
IvIg 22 1.09
Plasma Exchange 9 0.67
Methyl prednisolone 19 0.00
No Treatment 4 1.00
Not Applicable 3 -1.00
MRC disability 
scale
p = 0.000#
IvIg 22 2.50
Plasma Exchange 9 1.33
Methyl prednisolone 19 0.42
No Treatment 4 2.00
Not Applicable 3 -1.67
# Significance of influence of treatment options on mean improvement in disability scores
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The mean improvement in GBS disability scores from admission to 
the end of 8 weeks was calculated for AIDP subtype of GBS patients which 
is shown in the table 21 below.
Table-21 Mean improvement in disability scores for AIDP patients with 
various treatment options
Disability Scale Treatment Option
Total 
Numbers
Mean 
Improvement
GBS disability 
scale
p = 0.116#
IvIg 18 1.06
Plasma Exchange 6 0.67
Methyl prednisolone 15 0.13
No Treatment 4 1.00
MRC disability 
scale
p = 0.043#
IvIg 18 2.39
Plasma Exchange 6 1.33
Methyl prednisolone 15 0.53
No Treatment 4 2.00
# Significance of influence of treatment options on mean improvement in disability scores
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DISCUSSION
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DISCUSSION
In the present study totally 63 patients were enrolled from January 
2006  to  December  2007.   Patients  who  got  initially  admitted  in  the 
emergency  medical  ward,  were  subsequently  transferred  to 
medical/neuromedical ward or to the intensive medical care unit according 
to the severity of illness and its progression.
Among the total 63 patients registered, most patients were noted in the 
20 to 40 year age group (50.8%).  Only 3.2% of patients were elderly ( >60 
years).  The number of patients represented by <20 years age group may not 
reflect  the  true  incidence  in  our  study,  because  the  total  health  care  of 
pediatric age group patients is provided by the Institute of Child Health, a 
separate hospital attached to Madras Medical College.  Most surveys show a 
slight peak in late adolescence and young adult.  Some studies show a peak 
also in the elderly age group.  Dowling et al89 has reported a bimodal peak in 
the age specific incidence.  Whereas in our study no such phenomenon has 
been observed.
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Several studies have shown a slight male5,6  preponderance for GBS. 
In the present study also there is a male preponderance (55.6% vs 44.4%) 
with a male : female ratio of 1.25 : 1.  A similar preponderance is noted in 
the subtypes of GBS also.
In  our  study,  GBS is  noted  in  all  months  of  a  year  with  a  slight 
increase in the months from June to October, which is the end of summer 
and  the  beginning  of  rainy  season.   Several  studies  have  shown  such  a 
seasonal90 clustering.
Several  studies  had  established  that  the  prior  infection  may  be  a 
precipitating event  for  GBS, and it  can occur in about  60-70% of cases. 
12,77,91,92  Whereas the antecedent illness according to Ashok et al93 was 49% 
and Sunder et al94 was 52%.  We have noted 46% (29 patients) of patients 
with  antecedent  illness  which  include  diarrhea,  respiratory  infection, 
pregnancy, chicken pox and surgery.  54% of our patients did not have any 
specific preceding illness.  Each 20.6% of patients had respiratory infection 
or diarrhea as preceding illness.
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Typical pattern of ascending type areflexic quadriparesis was noted in 
47.6% of patients and simultaneous onset of illness in all 4 limbs + cranial 
nerve involvement was noted in 27% of patients.  Pain as a predominant 
feature in addition to weakness was observed in 5 patients (8%) of cases.  In 
this  group,  2  patients  landed  up  in  Rheumatology  Department  with  a 
provisional diagnosis of inflammatory myopathy and was later transferred to 
Neurology ward.
Cranial  nerve  involvement  in  the  form  of  either  facial  or  bulbar 
weakness was noted in 27 patients (42.7%) and 8 patients had both facial 
and bulbar weakness.  Sundar et al94 showed facial involvement in 39% of 
cases and bulbar involvement in 43% of cases.  Kaida et al95 showed facial 
involvement in 77% of cases and bulbar involvement in 65% of cases.  Our 
study  shows  facial  nerve  involvement  in  34.9%  of  cases  and  bulbar 
involvement in 20.6% of cases.   Opthalmoparesis  as a feature was noted 
only in MFS.
Autonomic  dysfunction  in  GBS  ranged  from  isolated  tachy  or 
bardycardia without hemodynamic disturbance to severe form of illness like 
Sudden Cardiac Death.  The incidence varied in several studies ranging from 
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17% by  Ashok  et  al93 to  33%  by  Sundar  et  al94.   In  the  present  study 
autonomic dysfunction was noted in 42.9% of patients.   In the course of 
illness 5 patients had severe postural hypotension and all these patients had 
poor  outcome  in  the  form of  death.   Hence  we  believe  severe  postural 
hypotension may be a predictor of poor prognosis.
It is well known that the rapidity of attaining peak disability is a poor 
prognostic  sign.   In  our  study  7  patients  (11%)  attained  peak  disability 
within 2 days, 29 patients (46%) attained peak disability in 3-8 days, 20 
patients (32%) attained peak disability in 15-28 days.  Totally 37 patients 
(58.7%) presented with peak disability within 8 days which is a high risk 
group for poor outcome.96
Nerve  conduction  studies  were  done  in  all  except  for  8  patients, 
because  of  early  death  or  difficulty  to  mobilize.   Prolongation  of  distal 
latency was the commonest abnormality noted (97%) in GBS patients with 
AIDP  subtype.   F-wave  abnormality  in  the  form  of  impersistance  or 
prolongation  of  minimum  latency  was  the  next  commonest  abnormality 
noted (87.2%) in GBS as a whole and in its sub type AIDP (92.7%).
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In the present study, nerve conduction study was not done on many 
patients in the initial few days or weeks, due to difficulty in mobilizing the 
sick  patients  from imcu  or  medical  wards  to  the  Neurology  department 
where the facility is available.  Hence electrophysiological parameters are 
not  used to assess  or  predict  the prognosis  in a  particular  patient  in this 
study.  But they are helpful to categorize GBS subtypes and to monitor the 
progress.
Out  of  the  total  63  patients,  AIDP  formed  the  bulk  (68.3%)  and 
AMSAN constituted 12.7% of cases.  AMAN was noted in 4.8% and MFS 
in 7.9% patients.  Three patients presented in an acute and severe form of 
illness  which  bulbar  weakness  and  autonomic  dysfunction  on  whom no 
specific  investigation or treatment  was effectively initiated except  for  the 
respiratory  support  and  symptomatic  treatment.   All  the  three  patients 
expired within one or two days and hence this group increases the overall 
mortality percentage of GBS patients.  This type of fulminant course was 
noted in 5 to 20 % of GBS cases by Alan R. Berger.76
In our  study IvIg was administered  to  22 patients  (34.9%),  plasma 
exchange was given to 9 patients (14.3%) and injection methyl prednisolone 
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was  given  to  25  patients  (39.6%).   As  already  noted  3  patients  with 
fulminant form of illness were not able to receive either of these treatment 
modality  and  were  also  not  grouped  in  any  of  the  GBS  subtypes 
(unclassified in our study).
Respiratory  muscle  weakness,  necessitating  ventilatory  support  in 
GBS  is  an  important  cause  for  mortality  and  morbidity.   Apart  from 
periodically  assessing  the  motor  power  of  limbs,  patient’s  adequacy  of 
respiratory function was done traditionally by Single Breath Count (SBC), 
cough reflex and neck muscle weakness.  Apart from this, the peak flow rate 
at one second in PEF meter was used in the study to objectively assess and 
document  the  respiratory  adequacy.   Three  attempts  were  given and  the 
average score was noted.  The PEFR of >500 correlated with SBC of >30 
indicating  adequate  power  of  respiratory  muscles.   The  PEFR  of  <100 
correlated with SBC<10 indicating an impending ventilatory dependence. 
The PEFR of 100-300 and 300-500 correlated with SBC of 10-20 and 20-30. 
Watchful expectancy has to be done for those with SBC of 10-20 (PEFR 
100-300).  All the 4 parameters (SBC, PEFR, Cough reflex, neck weakness) 
used in the study adequately predicted the need for ventilatory need.
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38 patients were admitted in our study with admission disability score 
of more than 3 in GBS disability scale and >5 in MRC disability scale.  They 
constituted  60.3%  of  the  total  patients  registered.   Good  outcome  is 
considered  when  the  patient  is  able  to  walk  which  is  a  score  of  ≤  3  in 
Hughe’s  GBS  disability  scale  and  ≤5  in  MRC  disability  scale.   Poor 
outcome is considered when the patient chair or bed bound, ventilator or 
expired,  which is a score of >3 in GBS disability scale  and >5 in MRC 
disability scale.  In our study at the end of 8 weeks, 24 patients had GBS 
disability score of >3 (MRC disability score >5) which contributed 38.1% of 
the total admitted patients.
Totally  19  patients  needed  ventilatory  support  which  constituted 
31.7% of  the  total  admission.   In  various  studies  a  similar  incidence  is 
noted.98,99  Lawn  et  al97 noted  that  53%  of  patients  needed  ventilatory 
support, whereas Kalitha et al102 noted only in 10% of patients.  In the AIDP 
subtype  27.9%  of  patients  needed  ventilatory  support  whereas  in  the 
AMSAN type the need was for 50% cases.
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Totally 10 deaths are recorded in our study which constituted 15.9% 
of the total admission.  Even in well equipped centers with aggressive ICU 
care, the mortality is noted to be around 5-10%76 and 4-15%.100,101
Totally 5 patients required tracheostomy for  the need of prolonged 
ventilation which constituted 7.9% of the total admission.
Among the 10 patients who had expired autonomic disturbance and 
high grade disability at  presentation were noted in 9 patients  and all  the 
patients who expired reached their peak disability within 8 days of onset of 
symptoms.  Bulbar dysfunction noted in 7 out of 10 patients and diarrhea 
was noted in only 4 patients.
Among the 20 patients who were ventilated autonomic  disturbance 
was noted in 13 patients, in 16 patients peak disability was reached before 8 
days  and  high  grade  disability  at  presentation  was  noted  in  17  patients, 
whereas diarrhea was noted in only 8 patients.
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Totally 27 patients (47.4%) had cranial nerve involvement and the rest 
did not.  When the cranial nerve involvement was present, good outcome 
was  noted  in  17.5% of  patients  and  poor  outcome  was  noted  in  29.8% 
patients.   Whereas  in  patients  without  cranial  nerve  involvement  good 
outcome was noted in 40.4% of patients and poor outcome was noted only in 
12.3% of patients.  The value is statistically significant (P = 0.002).
Totally  26  patients  (45.6%)  had  autonomic  disturbance.   When 
autonomic dysfunction was present 19.3% of patient had good outcome and 
26.3% had poor outcome.  Whereas in the absence of autonomic dysfunction 
good outcome was noted in 15.8% of patients.   The value is statistically 
significant (P = 0.029).
Totally 29 patients had antecedent illness and diarrhea was noted in 
13  patients  (22.8%).   In  the  patients  with  diarrhea,  good  outcome  was 
present  in  7%  of  patients  and  poor  outcome  was  present  in  15.8%  of 
patients.  The value is not statistically significant (P = 0.165).
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Totally 34 patients attained peak disability ≤ 8 days for this group of 
patients, good outcome was noted in 28.1% of patients and poor outcome 
was noted in 31.6% of patients.  Whereas for those patients who had not 
attained peak disability in ≤ 8 days the good outcome was noted in 29.8% of 
patients and poor outcome was noted in only 10.5% of patients.  The value is 
statistically significant (P = 0.044).
Totally 20 patients were admitted with ≤ 3 GBS disability score (≤ 5 
MRC disability score) and 37 patients with > 3 GBS disability score ( > 5 
MRC disability score) and 37 patients with > 3 GBS disability score ( > 5 
MRC disability score).  At the end of 8 weeks for those patients who were 
with ≤ 3 GBS disability scale, good outcome was noted in 29.8% of patients 
and poor outcome was noted in 38.6% of patients.  Though good outcome 
appears to be similar for both groups, they differ profoundly in terms of poor 
outcome.  The value is statistically significant (P = 0.001).
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Among  the  22  patients  who  were  treated  with  IvIg 14  patients 
(24.6%),  had  good  outcome  and  8  patients  (14.0%)  has  poor  outcome. 
Among the 9 patients who were treated with plasma exchange, 6 patients 
had good outcome and 3 had poor outcome.  Among the 19 patients, who 
were  treated  with  injection  methyl  prednisolone,  8  patients  had  good 
outcome and 11 patients had poor outcome.  The values obtained are not 
statistically significant (P =  0.076).
Among the IvIg treated 18 AIDP patients,  1 required tracheostomy 
(5%)  and  among  the  methyl  prednisolone  treated  15  AIDP  patients  4 
required tracheostomy (26%).
Among  the  IvIg treated  18  AIDP  patients,  5  required  ventilatory 
support (27%) and among the methyl prednisolone treated group 7 required 
ventilatory support (46%).
Among  the  IvIg treated  18  AIDP  patients,  1  patient  expired  and 
among the methyl  prednisolone  treated  15  AIDP patients,  3  had  expired 
(20%).
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The  IvIg treated  AIDP  patients  clearly  showed  less  percentage  of 
death, need for ventilatory support and tracheostomy when compared with 
methyl prednisolone treated patients, though the values are statistically not 
significant.   The  other  subtypes  and  variables  are  very  small  and  hence 
cannot be compared.
Among the AIDP patients,  who presented with severe  disability  at 
admission(25), 12 were treated with IvIg,  4 with plasma exchange and 9 with 
methyl prednisolone.
The outcome was good for 7 patients (58.3%) and poor for 5 patients 
(41.6%) in the IvIg treated group.  The outcome was good for 2 patients and 
poor for 2 patients in the plasma exchange treated group.  The outcome was 
good for 3 patients (33%) and poor for 6 patients (66%).
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Among the AMSAN patients, who presented with severe disability at 
admission,  3  each were treated with IvIg and methyl  prednisolone and 2 
patients were treated with plasma exchange.  The outcome was good for 2 
and poor for 1 patient, treated with IvIg, whereas all 3 patients had poor 
outcome in methyl prednisolone treated group.  Plasma exchange resulted in 
1 good and 1 poor outcome.
Even in the group of patients who presented with severe disability ( > 
3  in  GBS  disability  score)  at  admission,  among  the  AIDP  patients  the 
outcome appears to be better for those treated with IvIg compared to methyl 
prednisolone.  Among the AMSAN patients also, the outcome is poor for the 
methyl  prednisolone  treated  3  patients.   The  values  are  statistically  not 
significant.
Among the 12 AIDP patients, who presented with severe disability at 
admission and treated with IvIg, 1 out of 12 required tracheostomy (8%) and 
there was no death in this group.
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Among the 9 AIDP patients, who presented with severe disability at 
admission  and  treated  with  injection  methyl  prednisolone,  6  out  of  9 
required tracheostomy (33%) and there were 3 deaths in this group (33%).
Among  the  AIDP patients  who presented  with  severe  disability  at 
admission  itself,  the  need  for  ventilatory  support  with  or  without 
tracheostomy and the death are more in methyl prednisolone treated group 
than in the IvIg treated group.
The other variables and subtypes are too small to compare.
The mean improvement in GBS disability scores from admission to 
the end of 8th week was calculated for each treatment modality.  For IvIg it is 
1.09, for plasma exchange it is 0.67 and for methyl prednisolone it is 0.00. 
The values are statistically significant (P = 0.02).
Similarly  the  mean  improvement  in  MRC  disability  scores  from 
admission to the end of 8th week was calculated.   For IvIg it  is 2.05, for 
plasma exchange it  is  1.33 and for  methyl  prednisolone  it  is  0.42.   The 
values are statistically significant (P = 0.00).
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For AIDP subtype of GBS patients, the mean improvement in GBS 
disability scores from admission to the end of 8th week was calculated.  For 
IvIg it is 1.06, for plasma exchange it is 0.67 and for methyl prednisolone it 
is 0.13.  The values are statistically not significant.
Similarly for AIDP patients, the mean improvement in MRC disability 
scores from admission to the end of 8th week was calculated.  For IvIg it is 
2.39, for plasma exchange it is 1.33 and for methyl prednisolone it is 0.53. 
The values are statistically significant (P = 0.0).
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CONCLUSION
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CONCLUSION
 A significant proportion of patients present with peak disability within 
8 days of onset of illness to whom definite treatment options are to be 
made available to enhance a good and early recovery, because this is 
the group associated with poor outcome.
 The mean improvement in GBS disability scale from admission to the 
end of 8th week is more for IvIg treated patients when compared to 
methyl prednisolone treated group, which is statistically significant.  It 
is also applied well to the AIDP subtype of GBS.
 Though  statistically  not  significant  in  this  study,  injection  methyl 
predisolone is associated with high percentage of poor outcome when 
compared to IvIg and plasma exchange.
 The  prolonged  morbidity  of  the  illness  evidenced  by  the  need  for 
tracheostomy is more for those treated with methyl prednisolone when 
compared to other definite treatment options.
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 Peak expiratory flow rate can also be used as an objective measure to 
assess the respiratory function, which is handy, and it correlates with 
the standard assessment like single breath count.
 Autonomic dysfunction, bulbar weakness, rapidity of onset of illness, 
severe grade disability and diarrhea are significantly correlating with 
poor outcome.
 Postural hypotension was noted in all patients who had expired and it 
needs  further  analysis,  as  a  specific  prognosticating  parameter  in 
patients having autonomic dysfunction.
 A high index of suspicion is needed to diagnose GBS types like those 
who present with pain as the predominant feature.
 A small  but  significant  group of  patients  present  with a  fulminant 
form of disease for whom the prognosis is the worst in spite of good 
supportive measures and imcu care.
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Name : Occupation:
Age/Sex : DOA:
Address : IMCU:
Clinical contributes;
History : Mode of onset: Assc pain
Details of progression Autonomic symptoms
Peak of weakness: Resp. distress
Sensory symptoms: Post H/O similar illness
Antecede nil illness: URI/ AGE / Surgery/ 
Others:
Examination
General Exam:
Cranial nerve:
SMS: Tone:
Bulk:
Power:
Reflexes: Superficial:
DTR:
Sensory system:
Cerebellum
Gait:
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ANS:
GBS disability grading:
Modified Hughes:
MRC:
Laboratory contributes:
CBC:
Biochemical Parameters:
Radiology:
Electro physiology:
CSF:
Others:
Therapeutic Contributes:
Mode of Primary Treatment:
Others: Ventilatory support:
Secondary complication:
Outcome measurement:
4 weeks:
8 weeks:
Follow up details:
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Name: Unit: Date
Age/sex: MIN NO:
MOTOR NERVE CONDUCTION STUDY
NERVE LATENCY
milli sec
AMPLITUDE
MV
NCV
M/S
F WAVE
milli sec
SENSORY NERVE CONDUCTION STUDY
NERVE LATENCY AMPLITUDE VELOCITY
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